This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

This database contains 370 studies, archived under the term: "treatment outcome"

Click here to filter this large number of results.

Orally disintegrating donepezil: are the main caregivers of patients with Alzheimer’s disease more satisfied with this formulation of donepezil than with the traditional one?
Aim: To know whether caregivers of Alzheimer’s disease (AD) patients on donepezil treatment are more satisfied with the orally disintegrating tablet (ODT) formulation than with the film-coated tablets.; Patients and Methods: Multicenter, cross-sectional study of patients with probably AD by DSM-IV or NINCDS-ADRDA criteria, on monotherapy with donepezil, ODT or film-coated tablets. Satisfaction with treatment […]

Transdermal rivastigmine patch in outpatient services in Austria: a naturalistic study in 103 patients with Alzheimer dementia
We performed a 6-month open-label study on the use of the transdermal rivastigmine patch in clinical routine in 103 patients with Alzheimer’s disease from 25 outpatient services in Austria. After baseline, safety and tolerability of the 10 cm2–rivastigmine patch was assessed at week 4, 12 and 24 in all patients. A Mini Mental State Examination […]

Domain-specific cognitive effects of tramiprosate in patients with mild to moderate Alzheimer’s disease: ADAS-cog subscale results from the Alphase Study
Objectives: Tramiprosate (homotaurine, ALZHEMEDTM) was recently investigated for its efficacy, safety and disease-modification effects in a Phase III clinical study in mild to moderate Alzheimer’s disease (AD) patients (the Alphase study). The primary cognitive endpoint measure of that study was the Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog). To characterize potential cognitive benefits of tramiprosate, the […]

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Background: Bapineuzumab, a humanized anti-amyloid-beta (Abeta) monoclonal antibody for the potential treatment of Alzheimer disease (AD), was evaluated in a multiple ascending dose, safety, and efficacy study in mild to moderate AD.; Methods: The study enrolled 234 patients, randomly assigned to IV bapineuzumab or placebo in 4 dose cohorts (0.15, 0.5, 1.0, or 2.0 mg/kg). […]

Effects of cranial electrical stimulation on sleep disturbances, depressive symptoms, and caregiving appraisal in spousal caregivers of persons with Alzheimer’s disease
Purpose: The purpose of this work was to investigate the effects of cranial electrical stimulation (CES) on sleep disturbances, depressive symptoms, and caregiving appraisal.; Methods: Thirty-eight participants were randomly assigned to receive active CES or sham CES for 4 weeks.; Results: Both intervention groups demonstrated improvement in study measures from baseline scores. A trend toward […]

Vascular care in patients with Alzheimer’s disease with cerebrovascular lesions-a randomized clinical trial
Objectives: To investigate whether vascular care slows dementia progression in patients with Alzheimer’s disease with cerebrovascular lesions on neuroimaging.; Design: Multicenter randomized controlled clinical trial with 2-year follow-up.; Setting: Neurological and geriatric outpatient clinics in 10 Dutch hospitals: three academic, five teaching, and two midsize community hospitals.; Participants: One hundred thirty community-dwelling patients with mild […]

Efficacy of a vitamin/nutriceutical formulation for moderate-stage to later-stage Alzheimer’s disease: a placebo-controlled pilot study
Recent studies demonstrated efficacy of a vitamin/ nutriceutical formulation (folate, vitamin B12, alpha-tocopherol, S-adenosyl methionine, N-acetyl cysteine, and acetyl-L-carnitine) for mild to moderate Alzheimer’s disease. Herein, we tested the efficacy of this formulation in a small cohort of 12 institutionalized patients diagnosed with moderate-stage to later-stage Alzheimer’s disease. Participants were randomly separated into treatment of […]

A prospective study of ventriculo-peritoneal shunting for idiopathic normal pressure hydrocephalus
Idiopathic normal pressure hydrocephalus (INPH) is a potentially treatable form of dementia but its diagnosis is difficult and the effectiveness of shunting remains controversial. This study investigates the clinical outcomes of ventriculo-peritoneal shunting in a controlled trial of 33 consecutive patients with INPH. Mean age was 77.2 years (range 58-92 years) and the duration of […]

Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients
Background: The current study aimed to compare the effects of different cholinesterase inhibitors on acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) activities and protein levels, in the cerebrospinal fluid (CSF) of Alzheimer disease (AD) patients.; Methods and Findings: AD patients aged 50-85 years were randomized to open-label treatment with oral rivastigmine, donepezil or galantamine for 13 weeks. […]

Efficacy and tolerability of Ginkgo biloba extract EGb 761 by type of dementia: analyses of a randomised controlled trial
Secondary analyses of a randomised controlled trial were performed to find out whether treatment effects of Ginkgo biloba extract EGb 761 differed by type of dementia. Three hundred ninety-five patients aged 50 years or above, with dementia with neuropsychiatric features were treated with EGb 761 (240 mg/day) or placebo for 22 weeks. Patients scored between […]

Try searching our database by another keyword...

To make a new query of the database, please enter your search terms below:

�

Contact Us